

# **Tuberculosis Drugs Market Research Report by Disease Type (Active TB and Latent TB), by Drug Class (Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs) - Global Forecast to 2025 - Cumulative Impact of COVID-19**

<https://marketpublishers.com/r/T5695F15F025EN.html>

Date: February 2021

Pages: 184

Price: US\$ 3,949.00 (Single User License)

ID: T5695F15F025EN

## **Abstracts**

### Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Tuberculosis Drugs Market is expected to grow from USD 1,622.15 Million in 2020 to USD 2,095.09 Million by the end of 2025.
2. The Global Tuberculosis Drugs Market is expected to grow from EUR 1,422.33 Million in 2020 to EUR 1,837.01 Million by the end of 2025.
3. The Global Tuberculosis Drugs Market is expected to grow from GBP 1,264.45 Million in 2020 to GBP 1,633.11 Million by the end of 2025.
4. The Global Tuberculosis Drugs Market is expected to grow from JPY 173,124.51 Million in 2020 to JPY 223,599.66 Million by the end of 2025.
5. The Global Tuberculosis Drugs Market is expected to grow from AUD 2,355.57 Million in 2020 to AUD 3,042.35 Million by the end of 2025.

### Market Segmentation & Coverage:

This research report categorizes the Tuberculosis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the Tuberculosis Drugs Market studied across Active TB and Latent TB.

Based on Drug Class, the Tuberculosis Drugs Market studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs. The First-line Anti-TB Drugs further studied across Ethambutol, Isoniazid, Pyrazinamide, and Rifampin. The Second-line Anti-TB Drugs further studied across Capreomycin, Ethionamide, Levofloxacin, and Streptomycin.

Based on Geography, the Tuberculosis Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

#### Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Tuberculosis Drugs Market including AstraZeneca, Bayer AG, Cipla Ltd., Lupin, Merck & Co., Novartis AG, Otsuka Novel Products, Pfizer, Sandoz International GmbH, and Sanofi.

#### Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so far and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

#### 360iResearch FPNV Positioning Matrix:

The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Tuberculosis Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

### 360iResearch Competitive Strategic Window:

The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. **Market Penetration:** Provides comprehensive information on the market offered by the key players
2. **Market Development:** Provides in-depth information about lucrative emerging markets and analyzes the markets
3. **Market Diversification:** Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. **Competitive Assessment & Intelligence:** Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. **Product Development & Innovation:** Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Tuberculosis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Tuberculosis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Tuberculosis Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Tuberculosis Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Tuberculosis Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Tuberculosis Drugs Market?

## Contents

### 1. PREFACE

- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Stakeholders

### 2. RESEARCH METHODOLOGY

- 2.1. Research Process
  - 2.1.1. Define: Research Objective
  - 2.1.2. Determine: Research Design
  - 2.1.3. Prepare: Research Instrument
  - 2.1.4. Collect: Data Source
  - 2.1.5. Analyze: Data Interpretation
  - 2.1.6. Formulate: Data Verification
  - 2.1.7. Publish: Research Report
  - 2.1.8. Repeat: Report Update
- 2.2. Research Execution
  - 2.2.1. Initiation: Research Process
  - 2.2.2. Planning: Develop Research Plan
  - 2.2.3. Execution: Conduct Research
  - 2.2.4. Verification: Finding & Analysis
  - 2.2.5. Publication: Research Report
- 2.3. Research Outcome

### 3. EXECUTIVE SUMMARY

- 3.1. Introduction
- 3.2. Market Outlook
- 3.3. Drug Class Outlook
- 3.4. Disease Type Outlook
- 3.5. Geography Outlook
- 3.6. Competitor Outlook

## **4. MARKET OVERVIEW**

- 4.1. Introduction
- 4.2. Cumulative Impact of COVID-19

## **5. MARKET INSIGHTS**

- 5.1. Market Dynamics
  - 5.1.1. Drivers
  - 5.1.2. Restraints
  - 5.1.3. Opportunities
  - 5.1.4. Challenges
- 5.2. Porters Five Forces Analysis
  - 5.2.1. Threat of New Entrants
  - 5.2.2. Threat of Substitutes
  - 5.2.3. Bargaining Power of Customers
  - 5.2.4. Bargaining Power of Suppliers
  - 5.2.5. Industry Rivalry

## **6. GLOBAL TUBERCULOSIS DRUGS MARKET, BY DISEASE TYPE**

- 6.1. Introduction
- 6.2. Active TB
- 6.3. Latent TB

## **7. GLOBAL TUBERCULOSIS DRUGS MARKET, BY DRUG CLASS**

- 7.1. Introduction
- 7.2. Combination Drugs
- 7.3. First-line Anti-TB Drugs
  - 7.3.1. Ethambutol
  - 7.3.2. Isoniazid
  - 7.3.3. Pyrazinamide
  - 7.3.4. Rifampin
- 7.4. Second-line Anti-TB Drugs
  - 7.4.1. Capreomycin
  - 7.4.2. Ethionamide
  - 7.4.3. Levofloxacin

#### 7.4.4. Streptomycin

### **8. AMERICAS TUBERCULOSIS DRUGS MARKET**

- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States

### **9. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET**

- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. South Korea
- 9.10. Thailand

### **10. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET**

- 10.1. Introduction
- 10.2. France
- 10.3. Germany
- 10.4. Italy
- 10.5. Netherlands
- 10.6. Qatar
- 10.7. Russia
- 10.8. Saudi Arabia
- 10.9. South Africa
- 10.10. Spain
- 10.11. United Arab Emirates
- 10.12. United Kingdom

## **11. COMPETITIVE LANDSCAPE**

- 11.1. FPNV Positioning Matrix
  - 11.1.1. Quadrants
  - 11.1.2. Business Strategy
  - 11.1.3. Product Satisfaction
- 11.2. Market Ranking Analysis
- 11.3. Market Share Analysis
- 11.4. Competitor SWOT Analysis
- 11.5. Competitive Scenario
  - 11.5.1. Merger & Acquisition
  - 11.5.2. Agreement, Collaboration, & Partnership
  - 11.5.3. New Product Launch & Enhancement
  - 11.5.4. Investment & Funding
  - 11.5.5. Award, Recognition, & Expansion

## **12. COMPANY USABILITY PROFILES**

- 12.1. AstraZeneca
- 12.2. Bayer AG
- 12.3. Cipla Ltd.
- 12.4. Lupin
- 12.5. Merck & Co.
- 12.6. Novartis AG
- 12.7. Otsuka Novel Products
- 12.8. Pfizer
- 12.9. Sandoz International GmbH
- 12.10. Sanofi

## **13. APPENDIX**

- 13.1. Discussion Guide
- 13.2. License & Pricing

## List Of Tables

### LIST OF TABLES

TABLE 1. CURRENCY CONVERSION RATES

TABLE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)



TABLE 19. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 20. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 21. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 22. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 23. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 24. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 25. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 26. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 27. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 28. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 29. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 30. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 31. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 32. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 33. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 34. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 35. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 36. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 37. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 38. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE,

2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 39. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 40. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 41. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 42. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 43. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 44. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 45. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 46. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 47. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 48. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 49. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 50. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 51. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 52. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 53. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 54. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 55. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 56. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 57. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 58. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 59. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 60. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 61. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 62. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 63. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 64. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 65. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 66. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 67. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 68. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 69. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 70. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 71. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 72. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 73. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 74. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 75. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 76. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 77. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY

DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 78. GLOBAL TUBERCULOSIS DRUGS MARKET: SCORES

TABLE 79. GLOBAL TUBERCULOSIS DRUGS MARKET: BUSINESS STRATEGY

TABLE 80. GLOBAL TUBERCULOSIS DRUGS MARKET: PRODUCT SATISFACTION

TABLE 81. GLOBAL TUBERCULOSIS DRUGS MARKET: RANKING

TABLE 82. GLOBAL TUBERCULOSIS DRUGS MARKET: MERGER & ACQUISITION

TABLE 83. GLOBAL TUBERCULOSIS DRUGS MARKET: AGREEMENT,  
COLLABORATION, & PARTNERSHIP

TABLE 84. GLOBAL TUBERCULOSIS DRUGS MARKET: NEW PRODUCT LAUNCH &  
ENHANCEMENT

TABLE 85. GLOBAL TUBERCULOSIS DRUGS MARKET: INVESTMENT & FUNDING

TABLE 86. GLOBAL TUBERCULOSIS DRUGS MARKET: AWARD, RECOGNITION, &  
EXPANSION

TABLE 87. GLOBAL TUBERCULOSIS DRUGS MARKET: LICENSE & PRICING

## List Of Figures

### LIST OF FIGURES

FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET: RESEARCH PROCESS

FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET: RESEARCH EXECUTION

FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)

FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)

FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)

FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)

FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2025 (USD MILLION)

FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET: MARKET DYNAMICS

FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS

FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2025 (%)

FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2025 (USD MILLION)

FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2025

FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, 2020 VS 2025 (USD MILLION)

FIGURE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, 2020 VS 2025 (USD MILLION)

FIGURE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)

FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)

FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025

FIGURE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2020 VS 2025 (USD MILLION)

FIGURE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2020 VS 2025 (USD MILLION)

FIGURE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, 2020 VS 2025 (USD MILLION)

FIGURE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, 2020 VS 2025 (USD MILLION)

FIGURE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, 2020 VS 2025 (USD MILLION)

FIGURE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, 2020 VS 2025 (USD MILLION)

FIGURE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2020 VS 2025 (USD MILLION)

FIGURE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, 2020 VS 2025 (USD MILLION)

FIGURE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, 2020 VS 2025 (USD MILLION)

FIGURE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, 2020 VS 2025 (USD MILLION)

FIGURE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, 2020 VS 2025 (USD MILLION)

FIGURE 32. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 33. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 34. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 35. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 36. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 37. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 38. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 39. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY



GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 40. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 41. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 43. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 44. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 45. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 46. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 47. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 48. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 49. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 50. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 51. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 52. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 53. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 55. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 56. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 57. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 58. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 59. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 60. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 61. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 62. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 63. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 64. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 65. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 66. GLOBAL TUBERCULOSIS DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX

FIGURE 67. GLOBAL TUBERCULOSIS DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS

FIGURE 68. GLOBAL TUBERCULOSIS DRUGS MARKET: COMPETITOR SWOT ANALYSIS

FIGURE 69. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TUBERCULOSIS DRUGS MARKET, BY TYPE



## I would like to order

Product name: Tuberculosis Drugs Market Research Report by Disease Type (Active TB and Latent TB), by Drug Class (Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs) - Global Forecast to 2025 - Cumulative Impact of COVID-19

Product link: <https://marketpublishers.com/r/T5695F15F025EN.html>

Price: US\$ 3,949.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T5695F15F025EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970